Liquid Biopsy · Cancer Monitoring

Advanced Cancer Monitoring for Earlier Detection & Peace of Mind

LIQOMICS liquid biopsy helps detect cancer recurrence earlier with a simple blood test.

Non-invasive blood test Early detection of recurrence Used by leading oncologists

Post-Diagnosis Monitoring: This test is for patients already diagnosed with cancer and is not intended for general cancer screening.

Talk To Us To Find This Test Is Right For You

Trusted by Researchers, Clinicians, and Patients

Oncologist-Led

Founded by a hemato-oncologist who understands the daily challenges of patients and doctors.

Certified Laboratory

Our facility operates under strict RiliBÄK and ISO standards to ensure clinical precision.

Expert Clinical Trust

Collaborating with leading oncologists across Europe to integrate precise molecular monitoring into individual patient care plans.

Next-Gen Genomic Innovation

Born from breakthrough research in Germany, our proprietary technology defines the next frontier of ultra-precise molecular cancer monitoring.

Your Journey, Our Support

After Treatment, One Question Remains…

The fear of cancer returning can be overwhelming. Traditional monitoring methods often detect changes only when they are already advanced, leaving you in uncertainty.

Our Liquid Biopsy: A New Era of Precision

LIQOMICS' advanced liquid biopsy technology offers a non-invasive way to detect signs of cancer through a simple blood test, providing your doctor with crucial insights.

  • Early Detection of Recurrence
  • Personalised Treatment Insights
  • Non-Invasive Monitoring (simple blood test)
  • Reduced Anxiety, Greater Peace of Mind

"For you, this means less burdensome examinations, more precise information for your doctor, and ultimately, better treatment outcomes and a greater sense of control over your health."

Our Solutions

Find the Right Monitoring
for Your Cancer Type

Note: Our tests are specifically designed for patients currently in treatment or follow-up care.

What are you monitoring?

Lymphoma originates in the lymphatic system (the body's immune network). Solid Tumours are cancers that form a physical mass in specific organs, such as the lungs, breast, or colon. Selecting the correct category ensures your monitoring test focuses on the most relevant genetic signatures.

Still not sure? Contact us for guidance ↓
Lymphoma

LymphoVista

A specialised monitoring test for patients who have been treated for lymphoma, helping your doctor catch signs of return before symptoms appear.

Explore Lymphoma Monitoring
Solid Tumour

CancerVista

For patients with solid tumours, giving your oncologist an earlier window into how your body is responding to treatment.

Explore Solid Tumour Monitoring
General Inquiry

Not Sure Yet?

If you're unsure which test is right for you, or if your specific situation isn't listed, please contact us directly. Our team is here to help guide you.

Contact Us Directly
LymphoVista · Lymphoma Monitoring

Your Partner in Lymphoma Monitoring

If you've been treated for lymphoma, LymphoVista helps your doctor catch signs of return before symptoms appear. This means less anxiety for you and more precise, timely decisions for your care.

  • Earlier Detection Identifies signs of return before they become symptomatic, giving your doctor time to act.
  • Personalised Insights Tailored information specific to your lymphoma type and treatment history.
  • Non-Invasive & Safe All it takes is a simple blood test — no surgical biopsies or complex procedures.
  • Peace of Mind A greater sense of control and reduced fear of recurrence between appointments.
Learn More About LymphoVista →
LymphoVista
Lymphoma Monitoring Test
In-house IVD B-Cell Lymphomas 93.9% Sensitivity 10⁻⁶ Sensitivity
CancerVista
Solid Tumour Monitoring Test
In-house IVD Solid Tumours 93.2% Sensitivity 10⁻⁶ Sensitivity
CancerVista · Solid Tumour Monitoring

Advanced Monitoring for Solid Tumours

For patients with solid tumours, CancerVista gives your oncologist an earlier window into how your body is responding to treatment: or whether the cancer is returning.

  • Treatment Response Reveals how your body is responding, enabling your doctor to fine-tune your care plan.
  • Comprehensive Analysis Detects circulating tumour DNA across a wide range of solid tumour types.
  • Simple & Safe A blood test is a gentle alternative to invasive surgical biopsies.
  • Empowering Information Understand your disease status with greater clarity and confidence.
Learn More About CancerVista →
The Science of Detection

Defining the Path to Early Insight

To understand your results, it helps to understand the two pillars of our technology:

cfDNA

Cell-Free DNA are microscopic fragments of genetic material shed by cancer cells into your bloodstream. We capture these "genetic footprints" to see cancer activity at a molecular level.

MRD

Minimal Residual Disease refers to traces of cancer remaining in the body after treatment. These traces are invisible to traditional scans but detectable through our analysis.

By catching these signals early, we help your medical team transition from reactive waiting to proactive monitoring—giving you a vital head start in your ongoing care.

Process

Your Path to Personalised Monitoring

Think of our technology as a high-precision early warning system. While traditional scans look for visible changes, we look for microscopic "genetic footprints" that cancer cells leave behind in your blood. By catching these signals long before they show up on a scan, we give your medical team a vital head start, turning complex genomic analysis into a simple, clear roadmap for your ongoing care.

1

Talk to Your Doctor

Start the conversation. You and your oncologist decide together if our "early warning system" fits your care plan.

2

Simple Blood Draw

Just a routine check-up. No surgery or hospital stays: just a standard blood draw that takes only a few minutes.

3

Advanced Lab Analysis

Expert analysis in Germany. Our lab looks for tiny "genetic footprints" that are far too small for any scan to see.

4

Report for Your Doctor

Clear answers. Your doctor gets a straightforward report that helps them guide your treatment with more confidence.

Start Your Journey to Earlier Detection
Get Started

Prepare for Your Next Doctor's Visit

Download our Physician Conversation Guide. This detailed PDF includes clinical data, eligibility criteria, and a list of specific questions to help you and your oncologist decide if LIQOMICS is right for your care.

Get Your PDF Conversation Guide

We'll email you the tailored PDF guide immediately.
No obligations, no sales calls, no spam.

Our Advantage

Why Choose LIQOMICS?

Ultra-Sensitive Detection

We catch microscopic signals of cancer that traditional scans often miss.

Personalised Approach

Your test is built specifically for your body’s unique genetic footprint.

Research-Driven Innovation

Born from breakthroughs at the University of Cologne, built on years of study.

Non-Invasive & Safe

No hospital stay or surgery required — just a routine, painless blood test.

Fast Turnaround

Quick answers to help you and your doctor make decisions without delay.

Made in Germany & EU

Proudly developed and tested in Germany under the highest quality standards.

Your Questions Answered

Common Questions

About liquid biopsy and cancer monitoring for patients.

No. LIQOMICS technology is specifically engineered to detect Minimal Residual Disease (MRD) in patients who have already received a cancer diagnosis. It is not intended for, or validated as, a screening tool for healthy individuals.
Coverage varies by insurance provider and region. We recommend contacting your insurance company directly to inquire about coverage for liquid biopsy tests. Our team can also provide necessary documentation to assist with your claim.
LIQOMICS tests are currently available in several European countries. Please contact us or your healthcare provider to confirm availability in your specific location.
No: the examination involves a simple blood draw, similar to a routine blood test. It is a minimally invasive procedure with little to no discomfort.
LIQOMICS tests utilise advanced technology validated through extensive clinical studies. Your oncologist will interpret the results in the context of your overall clinical picture — this is a tool to empower your care team, not replace their judgement.
Typically, results are available within a few business days after the lab receives your sample. Your oncologist will be notified directly and will discuss the findings with you.
LIQOMICS tests must be ordered by a qualified healthcare professional, such as your oncologist. Please discuss with your doctor whether a liquid biopsy is appropriate for your situation.
Our tests are designed for specific cancer types, including various lymphomas (LymphoVista) and solid tumours (CancerVista). Please refer to the detailed product pages or consult your doctor for more information.
A liquid biopsy is a non-invasive blood test that can detect cancer cells or DNA fragments released by tumours into the bloodstream: without needing a tissue biopsy. It offers a way to monitor cancer progression, treatment response, and recurrence.
MRD stands for Minimal Residual Disease — the very small number of cancer cells that may remain in the body after initial treatment. Detecting MRD early is crucial for guiding further treatment decisions and preventing relapse.

Call us Use our Contact form Chat with us on WhatsApp